Form 4 for IDXX Idexx Laboratories
Accepted 2022-05-23 00:00:00 ET · period of report 2022-05-20 · accession 0001567619-22-011529 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-23 | 2022-05-20 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | $141.60 | +706 | 51.3K | +1% | +$100.0K |
| D | 2022-05-23 | 2022-05-20 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | — | -706 | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-20 | M | A | 706 | $141.60 | 51,300.64 | D | — | — | (F1) Includes 9 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2022. |
| 2 | Derivative | Incentive Stock Option (right-to-buy) | 2022-05-20 | M | D | 706 | — | 0 | D | $141.60 · — to 2027-02-13 | 706 Common Stock | (F3) Not applicable. (F2) Grant of option to buy 706 shares of IDEXX Laboratories, Inc. common stock that vested in one installment on February 14, 2022. |